Key Highlights

  • 0.95 USD is the per-share loss built into the consensus EPS estimate of -0.95 for Immunic, Inc. (NASDAQ:IMUX), due to report third-quarter 2026 results ahead of the opening bell on November 13, 2026.
  • 0.80 USD was the second-quarter 2026 per-share loss, tied to a Deficit near USD 34.1 million, compared with a loss per share of USD 2.03 and USD 26.8 million during Q2 2025.
  • 155.1 million USD was the cash on hand on June 30, 2026, which management believes can finance operations into late 2027, while a February 2026 private Placement pushed interest income up to USD 1.3 million.
  • 110.79 million USD is the Market Value in the screening snapshot, and headline results from the Phase 3 ENSURE-1 and ENSURE-2 studies targeting relapsing multiple sclerosis should land before the close of 2026.

What Canadian Investors Can Expect From Immunic, Inc. (NASDAQ:IMUX) on November 13, 2026

The screening snapshot has Immunic, Inc. publishing third-quarter 2026 results before the opening bell on November 13, 2026, with a consensus EPS estimate of -0.95 and a market value of USD 110.79 million. That estimate sits against a second-quarter loss of USD 0.80 a share, and any bigger gap would come from another weighted-average share total. For Q3 2025, coverage of the period cited a deficit of USD 25.6 million. No call time appeared in the snapshot.

Latest Quarter Results and Management Outlook at Immunic, Inc. (NASDAQ:IMUX)

Second-quarter 2026 R&D spending climbed to USD 25.9 million from USD 21.3 million, and G&A outlays grew to USD 9.4 million from USD 5.7 million, bringing total operating expenses to USD 35.3 million. Non-cash charges, chiefly stock compensation, totalled USD 7.2 million. Across six months the deficit was about USD 66.7 million, or USD 1.83 per share. Management guided to ENSURE results before year-end 2026, a US NDA filing in mid-2027 and approval aimed for 2028. A separate Phase 3 study for progressive multiple sclerosis patients should begin later in 2026. CEO Erik Lundgren said the company has the Capital to deliver on its priorities.

Liquidity, Valuation and Risk Factors at Immunic, Inc. (NASDAQ:IMUX)

The USD 155.1 million of cash on June 30, 2026 sits beside second-quarter operating expenses of USD 35.3 million, so one quarter of spending absorbs roughly 23% of the balance (calculated). Weighted-average shares numbered 42,513,839 for the second-quarter period, against 13,217,520 a year before. Immunic earns nothing from products yet and offered neither Revenue nor expense guidance. Risks cover dilution, regulatory timing, funding needs past late 2027, and trials that can succeed or Fail outright. Growth of about 27% in the second-quarter loss from a year earlier (calculated) points to rising spending.

Where Things Stand

Immunic, Inc. (NASDAQ:IMUX) heads into its report with a consensus EPS estimate of -0.95, a snapshot market value of USD 110.79 million and USD 155.1 million of cash on June 30, 2026. Second-quarter spending hit USD 35.3 million as late-stage work on multiple sclerosis and drug-interaction studies supporting a possible NDA went on. Management sees funding lasting into late 2027 and top-line ENSURE results arriving by year-end 2026, so what it says on timing will matter most. With no revenue, outcomes hinge on expenses, share count and interest earned. This note is for information only and is not a recommendation to buy or sell.